# RNN 1st Gen Model Zoetis Inc. Pharmaceutical preparations

Prediction models:
82.22% successful of 45 deals
$ 82.79 Last close price
at 23-feb-2018

ZTS

Model's trade recommendations 3.29% Return for period

15.63% Annual return

$39.06B Market Cap

β 1.07  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period 3.29%
3.37%
1.78%
52wk return 23.02%
53.66%
16.82%
52wk Range
52.54—82.79
2000.54—2399.63
Sortino ratio 3.42
Sharpe ratio 1.61
Norm. RMSE 0.88%
Downside risk 4.27%
Volatility 9.04%
  • 0.50 (0.63%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 484M
P/E 33.54
Shares Outstanding 485M
% Held by Insiders 0.31%
% Held by Institutions 94.18%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.69
EPS, estimated (last reported Q) $0.66
Total revenues $5 B
Net income $1 B